Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib combined with TH as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer
ChiCTR2200058810Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib, trastuzumab and paclitaxel in breast cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Pathological complete response rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200058810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058810.